ARISTADA
Drug
Alkermes, Inc.
Total Payments
$28.9M
Transactions
252,629
Doctors
32,454
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.5M | 56,473 | 14,376 |
| 2023 | $5.1M | 62,524 | 15,472 |
| 2022 | $3.6M | 53,727 | 13,541 |
| 2021 | $4.4M | 38,506 | 10,505 |
| 2020 | $3.1M | 11,558 | 3,434 |
| 2019 | $10.3M | 29,841 | 6,192 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14.6M | 6,339 | 50.5% |
| Unspecified | $5.9M | 407 | 20.4% |
| Food and Beverage | $5.6M | 238,114 | 19.3% |
| Travel and Lodging | $1.6M | 7,179 | 5.7% |
| Consulting Fee | $1.2M | 287 | 4.1% |
| Grant | $3,250 | 3 | 0.0% |
| Education | $943.60 | 300 | 0.0% |
Payments by Type
General
$23.0M
252,222 transactions
Research
$5.9M
407 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | Alkermes, Inc. | $1.6M | 0 |
| Pregnancy Registry Performance for Atypical Antipsychotics | Alkermes, Inc. | $1.5M | 0 |
| Aripiprazole lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode (APPRAISE) | Alkermes, Inc. | $957,059 | 0 |
| Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS) | Alkermes, Inc. | $664,348 | 2 |
| Comprehensive Treatment of Early Course Schizophrenia: A Nonrandomized Study of Long Acting Injectable Antipsychotic Medication Combined with Cognitive and Functional Skills Training | Alkermes, Inc. | $517,991 | 0 |
| Aripirazole lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode (APPRAISE) | Alkermes, Inc. | $450,000 | 0 |
| Long-Acting Antipsychotic Treatments in Community Telepsychiatry: Knowledge, Attitudes, and Perceived Barriers from Patients, Caregivers, and Providers' Perspective (South Carolina Example) | Alkermes, Inc. | $88,777 | 0 |
| Prescribing patterns of long acting injectable antipsychotics and all-cause hospital admissions in patients hospitalized with schizophrenia, schizoaffective disorders, or bipolar disorder | Alkermes, Inc. | $80,393 | 0 |
| Impact of aripiprazole medication adherence on learning and neuroplasticity in recent-onset schizophrenia: A comparison of long-acting injectable and oral formulations | Alkermes, Inc. | $15,000 | 0 |
Top Doctors Receiving Payments for ARISTADA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Psychiatry | Costa Mesa, CA | $199,072 | 238 |
| , MD PA | Psychiatry | Houston, TX | $192,218 | 256 |
| , M.D | Psychiatry | New York, NY | $186,221 | 268 |
| , MD | Psychiatry | Cheektowaga, NY | $182,462 | 186 |
| , M.D | Psychiatry | Loganville, GA | $177,975 | 183 |
| , MD | Psychiatry | Canton, OH | $176,727 | 276 |
| , MD | Psychiatry | Columbus, OH | $175,560 | 188 |
| , MD | Psychiatry | Columbus, OH | $171,622 | 282 |
| , MD | Psychiatry | Ada, OK | $168,851 | 219 |
| , M.D | Psychiatry | Las Vegas, NV | $167,856 | 150 |
| , M.D | Psychiatry | Pacoima, CA | $157,577 | 155 |
| , MD | Psychiatry | Amityville, NY | $153,025 | 141 |
| , M.D | Psychiatry | Prescott Valley, AZ | $152,591 | 174 |
| , M.D | Psychiatry | Sioux Falls, SD | $152,441 | 259 |
| , MD | Psychiatry | Lake Charles, LA | $146,711 | 213 |
| , MD | Psychiatry | Granada Hills, CA | $143,092 | 265 |
| , MD | Psychiatry | Saint Louis, MO | $136,528 | 133 |
| , M.D | Psychiatry | New York, NY | $135,846 | 183 |
| , MD | Psychiatry | Des Moines, IA | $135,824 | 223 |
| , MD | Psychiatry | Beachwood, OH | $134,070 | 133 |
| , M.D | Psychiatry | El Paso, TX | $129,837 | 188 |
| , MD | Psychiatry | Livonia, MI | $129,230 | 149 |
| , MD | Psychiatry | Mc Kees Rocks, PA | $126,743 | 150 |
| , M.D | Psychiatry | Coral Gables, FL | $126,678 | 180 |
| , MD, MPH | Psychiatry | Birmingham, AL | $124,584 | 199 |
Ad
Manufacturing Companies
- Alkermes, Inc. $28.9M
Product Information
- Type Drug
- Total Payments $28.9M
- Total Doctors 32,454
- Transactions 252,629
About ARISTADA
ARISTADA is a drug associated with $28.9M in payments to 32,454 healthcare providers, recorded across 252,629 transactions in the CMS Open Payments database. The primary manufacturer is Alkermes, Inc..
Payment data is available from 2019 to 2024. In 2024, $2.5M was paid across 56,473 transactions to 14,376 doctors.
The most common payment nature for ARISTADA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($14.6M, 50.5% of total).
ARISTADA is associated with 9 research studies, including "A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia" ($1.6M).